
Erasca Virtual Investor Event Highlighting Clinical Momentum Across Its RAS-Targeting Franchise
| DATE: | November 20, 2026 |
|---|---|
| TIME: | 8:00 AM EST |
| LOCATION: | Virtual |
About The Event
Join Erasca for a virtual investor event with company management to discuss updated Phase 1 data for ERAS-0015, a potential best-in-class pan-RAS molecular glue for RAS-mutant solid tumors, and other updates.
The event will follow an oral presentation of ERAS-0015 clinical data and a poster presentation of nonclinical ERAS-0015 and ERAS-4001 combination data at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, taking place Nov. 18–20 in Barcelona, Spain.
A live question and answer session will follow the formal presentations.